ClinicalTrials.gg
CompletedNCT05881304SWITCHEDUpdated Oct 21, 2026Results posted

Switching Individuals in Treatment for Opioid Use Disorder Who Smoke Cigarettes to the SREC

An interventional study of Standardized research e-cigarette (SREC) in Electronic Cigarette Use, sponsored by Massachusetts General Hospital. Completed at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-21.

Sponsored by Massachusetts General Hospital · Not applicable, Interventional, and Treatment

How we know

Updated Oct 21, 2026Results postedStudy documents posted+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
41
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 288 studies in Vaping with a site in United States — 66 open to participants now, 74 under way, 1 of them phase 3. Vaping · United States.

Enrollment
174th of 258
41 · median 71
Started
2024
with 30 others
No phase
206 of 288
39 open now
Registered
179th of 288
by date
Lead sponsor
6 of 288
Massachusetts General Hospital

Among the 288 studies in Vaping with a site in United States, this one is the 174th largest by enrollment of the 258 interventional ones that give a count, is one of 31 that started in 2024, is one of 206 with no phase, and was the 179th registered.

Vaping

404 studies on the registry are indexed under Vaping; 97 are open to participants now.

Browse Vaping studies →

Open to participants now

66 of the 288 studies in Vaping with a site in United States are open now. Recruiting first, the newest first:

61 more — sign in →

All 66 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 65 Vaping studies recruiting now, 33 (51%) set no upper age limit and 31 (48%) stop at 75 or younger; 13 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 288 studies in Vaping with a site in United States, or all of them as a file.
02

Study summary

The goal of this study is to conduct a pilot randomized waitlist-controlled trial to assess the feasibility, acceptability, and preliminary effects of substituting the NIDA standardized research e-cigarette (SREC) for combusted cigarettes in MOUD-TUD who are not ready to quit smoking. A waitlist controlled RCT using a mixed-methods sequential explanatory design will investigate the impact of SREC provision on: 1) tobacco use behavior (e.g., cigarettes per day [primary outcome], SREC use), 2) biomarkers (e.g., carbon monoxide, anabasine), 3) cigarette dependence and withdrawal, and 4) short-term health effects and tolerability (e.g., respiratory symptoms, substance use). In the proposed RCT, N=40 adults stable on MOUD with buprenorphine who report daily smoking recruited from MGH primary care practices will be randomly assigned to receive the SREC for 8 weeks, either immediately (iSREC), or after an 8-week delay (waitlist control [WLC]). They will be followed an additional 4 weeks after SREC provision ends (to 12 weeks in iSREC and 20 weeks in WLC).

03

Conditions studied

  • Electronic Cigarette Use

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18 years of age

    • Report daily cigarette smoking (>=10 cigarettes per day in the past week)
    • Not ready to quit smoking (not planning to quit in the next 30 days)
    • Willing to try e-cigarettes
    • In stable buprenorphine (BUP) treatment for opioid use disorder at an Massachusetts General Hospital-affiliated primary care clinic (in treatment for >=3 months without changes in BUP dose in the past 2 weeks and planning to remain on current BUP treatment for >=3 months).

Exclusion criteria

Exclusion Criteria:

  • Pregnant or breastfeeding
  • Using non-cigarette nicotine or tobacco products (e.g., e-cigarettes, cigarillos) recently (>3 days in past 30 days)
  • Report past 30-day use of behavioral or pharmacologic smoking cessation aids
  • Deemed inappropriate for participation by their OUD provider
  • Have an unstable psychiatric (e.g., past month suicidal ideation, active psychosis) or medical condition (e.g., \<1 year).
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
41 participants (actual)

Study arms

  • Experimental
    Immediate SREC provision (iSREC)

    Those randomized to the iSREC group will be provided a free 8-week supply of standardized research e-cigarettes (SRECs) and asked to try to switch completely to the SREC.

    Device: Standardized research e-cigarette (SREC)

  • Active comparator
    Delayed SREC provision waitlist control (WLC)

    Those in the WLC condition will receive SREC provision after an 8-week delay.

    Device: Standardized research e-cigarette (SREC)

Interventions

  • DeviceStandardized research e-cigarette (SREC)

    Patients will be provided with NIDA's standardized research electronic cigarette (SREC) for 8-weeks and asked to attempt to substitute the SREC for combusted cigarettes during the 8 weeks. Participants will be randomized in a 1:1 ratio to 1 of 2 conditions for 8 weeks: 1) immediate standardized research e-cigarette provision (iSREC) or 2) delayed SREC provision waitlist control (WLC). Those randomized to the iSREC group will be provided a free 8-week supply of SRECs and asked to try to switch completely to the SREC. Those in the WLC condition will receive SREC provision after an 8-week delay.

    Also known as: SREC

06

What researchers measure

Primary outcomes

  1. Cigarettes Smoked Per Day

    Change in cigarettes smoked per day (CPD) between randomized groups. Change in mean number of CPD in the past 7 days from start to end of the e-cigarette provision period comparing between randomized groups (iSREC group vs. WLC).

    Time frame: Baseline to Week 8

Secondary outcomes

  1. Study Enrollment

    Proportion of those screened identified as eligible. Proportion of those identified as eligible at screening who enroll in trial.

    Time frame: Screening to Baseline

  2. E-cigarette Use During E-cigarette Provision

    Difference between randomized groups in days per week of EC use during e-cigarette provision.

    Time frame: Baseline to Week 8 for iSREC and WLC

  3. Breath Carbon Monoxide

    Change in expired air carbon monoxide (CO) during e-cigarette provision.

    Time frame: Baseline to Week 8

  4. Anabasine

    Change in the percentage of participants who met anabasine-based tobacco abstinence criteria during e-cigarette provision.

    Time frame: Baseline to Week 8

  5. Study Completion

    Proportion of patients who complete the trial, defined as completing the final follow-up assessment (12 weeks for iSREC and 20 weeks for WLC)

    Time frame: Week 12 for iSREC, Week 20 for WLC

07

Results

Posted Oct 21, 2026

Participant flow

Participant flow — Overall Study
MilestoneImmediate Start (iSREC, Standardized Research Electronic Cigarette)SREC Waitlist Control (WLC)
Started2219
Completed1816
Not completed43

Outcome measures

PrimaryCigarettes Smoked Per Day

Change in cigarettes smoked per day (CPD) between randomized groups. Change in mean number of CPD in the past 7 days from start to end of the e-cigarette provision period comparing between randomized groups (iSREC group vs. WLC).

Time frame:
Baseline to Week 8
Reported as:
Mean · Number of Cigarettes per Day
Cigarettes Smoked Per Day
Number of Cigarettes per DayImmediate Start (iSREC, Standardized Research Electronic Cigarette)SREC Waitlist Control (WLC)
Cigarettes Smoked Per Day8.1 ± 4.71.4 ± 7.6
SecondaryStudy Enrollment

Proportion of those screened identified as eligible. Proportion of those identified as eligible at screening who enroll in trial.

Time frame:
Screening to Baseline
Reported as:
Count of participants · Participants
Study Enrollment
ParticipantsTotal
Number of Participants Screened Eligible113
Number of Participants Enrolled41
SecondaryE-cigarette Use During E-cigarette Provision

Difference between randomized groups in days per week of EC use during e-cigarette provision.

Time frame:
Baseline to Week 8 for iSREC and WLC
Reported as:
Mean · Days per week with e-cigarette use
E-cigarette Use During E-cigarette Provision
Days per week with e-cigarette useImmediate Start (iSREC, Standardized Research Electronic Cigarette)SREC Waitlist Control (WLC)
E-cigarette Use During E-cigarette Provision6.2 ± 1.21.8 ± 2.5
SecondaryBreath Carbon Monoxide

Change in expired air carbon monoxide (CO) during e-cigarette provision.

Time frame:
Baseline to Week 8
Reported as:
Mean · ppm
Breath Carbon Monoxide
ppmImmediate Start (iSREC, Standardized Research Electronic Cigarette)SREC Waitlist Control (WLC)
Breath Carbon Monoxide-10.6 ± 9.8-6.1 ± 11.0
SecondaryAnabasine

Change in the percentage of participants who met anabasine-based tobacco abstinence criteria during e-cigarette provision.

Time frame:
Baseline to Week 8
Reported as:
Number · Percent participants abstinent
Anabasine
Percent participants abstinentImmediate Start (iSREC, Standardized Research Electronic Cigarette)SREC Waitlist Control (WLC)
Baseline Anabasine Abstinence1428
Week 8 Anabasine Abstinence3529
SecondaryStudy Completion

Proportion of patients who complete the trial, defined as completing the final follow-up assessment (12 weeks for iSREC and 20 weeks for WLC)

Time frame:
Week 12 for iSREC, Week 20 for WLC
Reported as:
Count of participants · Participants
Study Completion
ParticipantsImmediate Start (iSREC, Standardized Research Electronic Cigarette)SREC Waitlist Control (WLC)
Study Completion1816

Adverse events

Collected over From enrollment to end of follow-up (SREC week 12, WLC week 20). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Immediate Start (iSREC, Standardized Research Electronic Cigarette)0/22 (0%)0/22 (0%)8/22 (36.4%)
Waitlist Control (WLC) During SREC Provision0/19 (0%)0/19 (0%)4/19 (21.1%)
Waitlist Control (WLC) During Control Period0/19 (0%)0/19 (0%)6/19 (31.6%)
Most frequent other events
Showing 10 of 16
Most frequent other events
EventImmediate Start (iSREC, Standardized Research Electronic Cigarette)Waitlist Control (WLC) During SREC ProvisionWaitlist Control (WLC) During Control Period
DepressionPsychiatric disorders1/221/192/19
StressGeneral disorders1/222/191/19
Body painMusculoskeletal and connective tissue disorders1/220/191/19
Common ColdRespiratory, thoracic and mediastinal disorders0/221/191/19
Manic EpisodePsychiatric disorders0/220/191/19
Hidradenitis FlareSkin and subcutaneous tissue disorders0/221/190/19
InfectionInfections and infestations1/220/191/19
PneumoniaRespiratory, thoracic and mediastinal disorders0/220/191/19
Root Canal PainGeneral disorders0/221/190/19
InsomniaPsychiatric disorders1/220/190/19

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Immediate Start (iSREC, Standardized Research Electronic Cigarette)SREC Waitlist Control (WLC)Total
Mean52 ± 1248 ± 1150 ± 12
Sex: Female, Male
Sex: Female, Male(Participants)Immediate Start (iSREC, Standardized Research Electronic Cigarette)SREC Waitlist Control (WLC)Total
Female4610
Male181331
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Immediate Start (iSREC, Standardized Research Electronic Cigarette)SREC Waitlist Control (WLC)Total
American Indian or Alaska Native000
Asian101
Native Hawaiian or Other Pacific Islander000
Black or African American213
White191736
More than one race011
Unknown or Not Reported000
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Immediate Start (iSREC, Standardized Research Electronic Cigarette)SREC Waitlist Control (WLC)Total
Hispanic or Latino022
Not Hispanic or Latino221739
Unknown or Not Reported000
08

Study locations

1 site
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2024 to primary completion in Dec 2025, 18 months.

Results were first posted in Oct 2026, 9 months after primary completion.

Of 184 non-industry interventional studies with no phase under Vaping, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 35. This study's 18 months is close to that.

Counting every sponsor, half of 208 studies reached it within 18 months; a quarter within 6 and three quarters within 32.

How these figures are worked out, and which studies are left out of them.

Registered
May 19, 2023
First posted
May 31, 2023
StartActual
Jun 3, 2024
Primary completionActual
Dec 31, 2025
CompletionActual
Dec 31, 2025
Results first posted
Oct 21, 2026
Last update
Oct 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Oct 21, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • EditedCigarettes smoked per daySmoked Per DayTime frame: Baseline 2 to 8 weeks → Baseline to Week 8
Oct 21, 2026
Secondary outcomes
4 edited, 1 time frame changed, 1 description edited
What changed in the outcomes
  • EditedStudy enrollmentEnrollmentTime frame: Baseline → Screening to Baseline
  • EditedE-cigarette use during eUse During E-cigarette provisionProvisionTime frame: During the 8 weeks of e-cigarette provision → Baseline to Week 8 for iSREC and WLC
  • EditedBreath carbon monoxideCarbon MonoxideTime frame: Baseline 1-Week 8 → Baseline to Week 8
  • EditedStudy completionCompletionTime frame: Baseline 2-12 weeks for iSREC (Baseline 2-20 weeks for WLC) → Week 12 for iSREC, Week 20 for WLC
  • Time frameAnabasineBaseline 1-Week 8 → Baseline to Week 8
  • DescriptionAnabasine: how it is measured was reworded
Oct 21, 2026
Show all 1 update
  1. Oct 21, 2026
    Results posted
    Primary outcomes 1 edited
    What changed in the outcomes
    • EditedCigarettes smoked per daySmoked Per DayTime frame: Baseline 2 to 8 weeks → Baseline to Week 8
    Secondary outcomes 4 edited, 1 time frame changed, 1 description edited
    What changed in the outcomes
    • EditedStudy enrollmentEnrollmentTime frame: Baseline → Screening to Baseline
    • EditedE-cigarette use during eUse During E-cigarette provisionProvisionTime frame: During the 8 weeks of e-cigarette provision → Baseline to Week 8 for iSREC and WLC
    • EditedBreath carbon monoxideCarbon MonoxideTime frame: Baseline 1-Week 8 → Baseline to Week 8
    • EditedStudy completionCompletionTime frame: Baseline 2-12 weeks for iSREC (Baseline 2-20 weeks for WLC) → Week 12 for iSREC, Week 20 for WLC
    • Time frameAnabasineBaseline 1-Week 8 → Baseline to Week 8
    • DescriptionAnabasine: how it is measured was reworded
    + 2 other changes: verification date and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT05881304
Responsible party
Joanna M. Streck, Ph.D. (Assistant Professor in Psychiatry, Massachusetts General Hospital) — Principal investigator
First posted
May 31, 2023
Start date
Jun 3, 2024
Primary completion
Dec 31, 2025
Completion
Dec 31, 2025
Results posted
Oct 21, 2026
Last update
Oct 21, 2026

Study contacts

Joanna M Streck, PhD
principal investigator · Massachusetts General Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion